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How high doses of intravenous IgG (IVIG) suppress autoimmune diseases 
remains unresolved. We have recently shown that the antiinfl  ammatory 
activity of IVIG can be attributed to a minor species of IgGs that is modifi  ed 
with terminal sialic acids on their Fc-linked glycans. Here we propose that 
these Fc-sialylated IgGs engage a unique receptor on macrophages that, 
in turn, leads to the upregulation of an inhibitory Fcγ receptor (FcγR), 
thereby protecting against autoantibody-mediated pathology.
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IgG antibodies are the primary media-
tors of protective humoral immunity 
against pathogens, but they can also be 
pathogenic. Acting as cytotoxic mole-
cules or as immune complexes, IgG auto-
antibodies are the principal mediators 
of autoimmune diseases such as immune 
thrombocytopenia (ITP), autoimmune 
hemolytic anemia (AHA), and systemic 
lupus erythematosus (SLE), and may 
contribute to other autoimmune dis-
eases, such as rheumatoid arthritis (RA), 
type I diabetes, and multiple sclerosis 
(1). IgG antibodies have been used ther-
apeutically for over a century. They 
were fi  rst used as antitoxins for the treat-
ment of infectious diseases in the prean-
tibiotic era (1, 2). Today, hyperimmune 
sera from human donors recovering 
from infection with specifi  c viruses, 
such as hepatitis B, cytomegalovirus, 
and varicella zoster, are used to provide 
protective immunity to susceptible pop-
ulations. In addition, pooled polyclonal 
IgG from the serum of thousands of do-
nors is currently used to provide re-
placement IVIG therapy for patients 
lacking immunoglobulins (3). At high 
doses (1 g/kg), IVIG is also widely used 
as an antiinfl   ammatory agent for the 
treatment of autoimmune diseases. This 
approach is based on an observation 
made in 1981 that administration of 
IVIG attenuated platelet clearance in a 
child with ITP (4). Since then, high 
dose IVIG has been widely used to treat 
patients with immune system disorders 
and is FDA approved for the treatment 
of ITP and Kawasaki’s Disease, an acute 
vasculitic syndrome, in addition to hu-
moral immunodefi   ciency and bone 
marrow transplantation. Off   label uses 
include the treatment of RA, SLE, mul-
tiple sclerosis, and scleroderma. Demand 
for IVIG has been increasing in recent 
years, resulting in shortages and restric-
tions in its use. In the United States, 
over 4 million grams of IVIG was used 
in 2004 at a cost of $500 million, more 
than half of which was off   label use.
The mechanisms by which high 
doses of pooled, monomeric IgG pro-
vide antiinfl  ammatory activity have been 
the subject of much speculation, stem-
ming from the fact that IgGs can form 
many diff   erent binding interactions 
through both their antigen binding and 
Fc domains. In this commentary, we will 
address the current models of IVIG anti-
infl  ammatory activity and review recent 
results that argue against these models 
and support an alternative, novel mecha-
nism of action. This new model accounts 
for the high dose requirement for IVIG 
in infl  ammatory diseases and for the 
dominant role of the Fc portion of the 
molecule, and suggests ways to improve 
therapeutics for autoimmune diseases.
Fc is key
In some cases, antigen binding alone 
might be suffi   cient to mediate the anti-
infl  ammatory eff  ects attributed to IVIG, 
for example, by blocking interactions 
between a proinfl  ammatory ligand and 
its receptor or by neutralizing its ability 
to elicit an infl  ammatory response. This 
Fab-mediated mechanism appears to 
underlie the therapeutic activity of 
IVIG in the treatment of toxic epider-
mal necrolysis, which has been attrib-
uted to inhibition of Fas-mediated 
epidermal cell death by antagonistic 
anti-Fas antibodies in the IVIG prepa-
ration (5). However, a generalized role 
for the antigen binding domain in the 
antiinfl  ammatory activity of IgG is un-
likely given that intact IVIG and its Fc 
fragments have equivalent antiinfl  am-
matory activity both in the clinical 
treatment of ITP (6) and in many ani-
mal models (7–9). We will therefore 
focus on the mechanisms by which the 
Fc region of IgG may function as an anti-
infl  ammatory molecule.
How IgG autoantibodies infl  ame: 
activating Fc𝗄Rs, neonatal Fc receptor, 
and complement
To understand how IVIG reverses in-
fl  ammation in autoimmune disease, it is 
helpful to consider how IgG autoanti-
bodies cause infl  ammation. The IgG Fc 
region couples antigen recognition to 
several eff  ector pathways, most notably 
the system of activating and inhibitory 
FcγRs, the complement family of mol-
ecules and their receptors, and the neo-
natal Fc receptor (FcRn) pathway, 
which is required for the extended 
in vivo half-life of IgG antibodies (10–13). 
Studies in animal systems and correla-
tive studies in human populations show 
that the proinfl   ammatory activities of 
IgG require the interaction of the Fc 
fragment of the antibodies with their 
cognate cellular FcγRs (1). Most hema-
topoietic cells express both activating 
and inhibitory FcγRs. The in vivo ac-
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from the net eff   ect of engaging both 
classes of receptors, which, in turn, is 
governed by the respective affi   nity con-
stants of individual IgG subclasses for 
specifi  c FcγRs (14).
FcγRs for IgG are the primary me-
diators of the proinfl  ammatory activity 
of IgG in the immunopathology of au-
toimmune diseases and are required for 
the protective action of IgG therapeu-
tics, such as the anti-CD20 monoclonal 
antibody (mAb) used to treat lym-
phoma. Thus, mice rendered geneti-
cally defi  cient in the activating FcγRs 
are protected from the pathogenic con-
sequences of autoantibodies in many 
disease models, including SLE, RA, 
ITP, AHA, and Goodpasture’s Disease 
(10). And tumor-specifi  c mAbs (IgG), 
designed to clear tumors, also fail to 
protect these mice (15). Studies in hu-
mans have similarly shown that the 
clinical response to antitumor antibod-
ies depends on activating FcγR genes. 
Indeed, patients with FcγR alleles that 
confer higher binding activity to the 
therapeutic IgG have improved clinical 
outcomes (16–18). FcγR alleles that 
confer hyperresponsiveness to IgG im-
mune complexes are also associated 
with autoimmune disease susceptibility 
in defi  ned populations (1).
In contrast to FcγRs, animal studies 
have generally failed to demonstrate a 
substantial contribution of the classical 
pathway of complement activation in 
models of IgG-mediated infl  ammation. 
Mice defi  cient in the C3 component 
of complement, for example, are not 
protected from IgG-mediated cytotox-
icity for complement-fi  xing antibodies 
in models of red cell, platelet, or B cell 
clearance (19). In several models of im-
mune complex-mediated infl  ammation, 
C3 has been shown to be dispensable 
as well (20). In some models of IgG-
mediated infl   ammation C5a receptor 
(C5aR)–defi   cient mice are protected 
(21, 22). In those cases where C5aR 
defi  ciency leads to protection, the pro-
posed mechanism is not through classi-
cal or alternative complement pathway 
activation of C5a, but rather through a 
direct activation of C5a by FcγR cross-
linking on eff  ector cells, which in turn 
results in C5aR-triggered up-regulation 
of FcγR expression on these eff  ector 
cells (21, 23).
Similar to mice lacking the activat-
ing FcγRs, mice defi  cient in FcRn are 
protected from pathogenic autoanti-
bodies. The long serum half-life of IgG 
results from its interaction with FcRn, a 
major histocompatibility complex class I 
homologue that associates with β2-
  microglobulin and is expressed on en-
dothelial cells. FcRn remains bound to 
internalized IgG at the acidic pH of the 
lysosomal vesicle, preventing its intra-
cellular degradation and allowing it to 
be recycled to the extracellular milieu 
(12, 13, 24). Disruption of the FcRn 
pathway in mice results in the rapid 
clearance of all IgG antibodies, includ-
ing pathogenic autoantibodies, which 
protect these mice from autoantibody-
driven infl  ammation (25–27).
The antiinfl  ammatory activity of IVIG
Three possible modes of action have 
been proposed to account for the anti-
infl   ammatory activity of the Fc frag-
ments of IVIG. These models take into 
account the mechanisms by which auto-
antibodies trigger infl  ammation and the 
high doses of IVIG that are required for 
protection (Fig. 1).
Since the in vivo data on the patho-
genicity of IgG autoantibodies and 
immune complexes do not generally 
support a role for the components of 
the complement cascade in autoanti-
body-driven infl  ammation, we will not 
consider that pathway in the mecha-
nisms of IVIG.
Model 1: competition for activating 
Fc𝗄Rs. The fi  rst model posits that high 
doses of intravenous IgG compete with 
pathogenic IgGs for activating FcγRs, 
thereby limiting their pathogenic po-
tential. Studies showing that mAbs that 
block activating FcγRs mimic the anti-
infl  ammatory activity of IVIG appear to 
support this model (28). Although this 
model recognizes the primary role of 
FcγRs in the pathogenesis of autoim-
mune-mediated infl  ammation, it fails to 
take into account the low affi   nity  of 
these receptors. IgGs interact with acti-
vating FcγRs (FcγRIII and IV) with 
affi   nity constants in the range of 10−6 to 
10−7. This ensures that these receptors 
are activated by IgG immune com-
plexes, which can form high avidity 
  interactions, and not by monomeric, 
circulating IgG. Competition for ac-
tivating FcγR might occur if IVIG 
preparations were contaminated with 
immune complexes. This is unlikely, 
however, as whole IgG and isolated 
IgG Fc regions have comparable antiin-
fl  ammatory activities. Even at the high 
doses of IVIG required to elicit antiin-
fl   ammatory activity, the serum IgG 
concentrations that can be achieved by 
injecting exogenous IgG into individu-
als with normal levels of circulating IgG 
are insuffi   cient to compensate for the 
low affi   nity constants of FcγRs for mo-
nomeric IgGs. In fact, at high doses of 
IgG, the resulting saturation of FcRn 
increases IgG catabolism, thus restoring 
the circulating concentration of IgG to 
a relatively narrow range. The fact that 
mAbs that block activating FcγRs 
mimic the antiinfl  ammatory activity of 
IVIG simply refl  ects the fact that patho-
genic immune complexes trigger in-
fl   ammation through these activation 
receptors; it does not indicate that IVIG 
and anti-FcγRs mAbs have a common 
mechanism of action (9, 28). Indeed, as 
will be described below, the antiinfl  am-
matory activity of IgGs in IVIG prepa-
rations increases as their affi   nity  for 
activating FcγRs decreases.
Model 2: high dose IgG saturation of 
FcRn. An alternative scenario to model 1 
is that saturation of FcRn by high lev-
els of exogenous IgG leads to the ca-
tabolism of pathogenic autoantibodies. 
It is diffi   cult to evaluate this theory ex-
perimentally, however, as removing or 
blocking FcRn in mice results in a rapid 
clearance of exogenous autoantibodies 
and drastically reduced serum IgG levels 
(27). Investigations of the eff  ect of IVIG 
in FcRn-defi  cient mice have relied ei-
ther on repeated infusion of IVIG, a 
situation that does not accurately model 
the use of IVIG, or evaluation of the 
purported protective eff  ect of IVIG at 
time points far beyond the peak of the 
disease. For example, a common animal 
model used to evaluate IVIG action is 
platelet depletion in mice mediated by COMMENTARY
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an antiplatelet antibody. In this model, 
platelet consumption reaches a nadir 
4 hours after introduction of the cyto-
toxic antibody; IVIG prevents platelet 
depletion through this time point. In 
FcRn-defi  cient mice, however, IVIG-
induced protection against platelet de-
pletion is not observed until 48–72 h 
after infusion of the cytotoxic antibody 
(25, 29). In another model, human 
polyclonal antibodies found in human 
bullous diseases (bullous pemphigoid, 
pemphigus foliaceus, and pemphigus 
vulgaris) were passively transferred to 
neonatal mice to induce disease. IVIG 
protected wild-type mice but did not 
protect neonatal FcRn-defi  cient mice. 
Little is known about the mechanisms 
by which these human antibodies trig-
ger disease in this model or about the 
expression of FcγRs or FcRn in neona-
tal mice, making it diffi   cult to draw any 
general conclusions about the mecha-
nism of IVIG protection (26).
Ruling out a role for FcRn satu-
ration in the antiinfl  ammatory  activ-
ity of IVIG would require an IVIG 
  preparation that binds FcRn and has a 
normal serum half-life but has no anti-
infl  ammatory activity. There are several 
experimental systems that fulfi  ll  these 
requirements. Deglycosylation of the 
conserved, Asn297 N-linked glycan on 
IgG or its Fc fragment with PNGase, 
for example, yields an IVIG preparation 
that retains FcRn binding and normal 
serum half-life but lacks its antiinfl  am-
matory activity (30, 31). Desialylation 
of the terminal sialic acid residues on 
the Asn297-linked glycan of IVIG has 
the same eff  ect (31). Thus, if saturation 
of FcRn by high dose IVIG is involved 
in its antiinfl   ammatory mechanism of 
action, these glycan-modifi  ed prepara-
tions of IVIG should not have lost ac-
tivity. Conversely, enriching IVIG for 
sialylated Fc glycoforms enhances its 
antiinfl  ammatory activity, thus reduc-
ing the dose of IVIG required for pro-
tection without aff  ecting the half-life of 
either the IVIG antibodies (31) or the 
pathogenic mouse serum antibodies 
(unpublished data). Again, this provides 
evidence against a role for FcRn in the 
antiinfl  ammatory activity of IVIG.
Model 3: induction of inhibitory Fc𝗄R 
expression. The fi  nal model posits that 
the antiinfl  ammatory  eff   ect of IVIG 
Fc fragments involves the inhibitory 
FcγRIIB. Triggering of eff  ector cells, 
such as macrophages, by IgG bound 
to target cells or by immune complexes 
occurs when FcγR signaling reaches 
a critical threshold. Changing the 
affi   nity of IgG for either activating or 
Figure 1.  Models for the mechanism of IVIG-mediated antiinfl  ammatory activity. (A) During 
an infl  ammatory response immune complexes consisting of autoantibodies (brown) and self-
antigens (green) activate innate immune effector cells (e.g., macrophages) by cross-linking cell surface 
FcγRs, which can lead to the destruction of self-tissues. Serum antibody half-life of normal (light 
brown) and autoreactive antibodies is regulated by FcRn (purple) expressed on endothelial cells. 
(B) Three models have been proposed to explain the antiinfl  ammatory activity of IVIG. In the fi  rst 
model, IVIG (consisting of a mixture of sialic acid–rich [red] and sialic acid–low [blue] antibodies) 
binds to activating FcγRs on immune effector cells, thereby blocking access of immune complexes to 
these receptors and inhibiting cell activation. The second model proposes that IVIG competes with serum 
IgG (including autoreactive antibodies) for recycling mediated by FcRn. Thus, serum and autoreactive 
antibodies would be cleared more rapidly and not reach the threshold level for initiating tissue 
destruction. In the third model, IVIG leads to up-regulation of the inhibitory FcγRIIB on immune 
effector cells, thus increasing the threshold level for cell activation by immune complexes.14  ANTIINFLAMMATORY ACTIVITY OF IVIG | Nimmerjahn and Ravetch
inhibitory receptors (by glycosylation 
modifi  cations, for example) or modu-
lating the absolute cell surface levels 
of these receptors will change the IgG 
concentration required to trigger cellu-
lar activation. In models of ITP, AHA, 
RA, and nephrotoxic nephritis, the abil-
ity of IVIG to protect mice from patho-
genic IgG antibody–driven responses 
depends on FcγRIIB (7–9, 25, 31, 32). 
The only other mouse strain in which 
IgG-mediated infl  ammation occurs but 
IVIG protection is lost is the op/op 
mouse, in which loss of the hematopoi-
etic growth factor colony-stimulating 
factor (CSF)-1 results in a depletion of 
CSF-1–dependent macrophage popula-
tions (7). IVIG administration to nor-
mal mice, but not op/op mice, increases 
the surface expression of FcγRIIB on 
a population of CSF-1–independent, 
“eff   ector” macrophages in the spleen 
(Fig. 2). These results imply that two dif-
ferent macrophage subsets are involved 
in the mechanism of IVIG action—
a subset that is dependent on CSF-1 
(and thus absent in op/op mice) that 
may act as a “regulator” of IVIG, and 
a CSF-1–independent, eff  ector subset, 
which mediates the infl  ammatory  re-
sponses to IgG–FcγR cross-linking. By 
engaging the regulatory macrophage, 
IVIG triggers a suppressive pathway 
that attenuates the ability of the eff  ector 
macrophages to respond to cytotoxic or 
immune-complexed IgG that cross-link 
activating FcγRs. This inhibition in-
volves increasing the surface expression 
of the inhibitory FcγRs, thereby rais-
ing the threshold required for trigger-
ing activating FcγRs. The mechanism 
by which IVIG engaged regulatory 
macrophages, which then triggered the 
up-regulation of inhibitory FcγRs ex-
pression on the eff  ector population, re-
mained unknown. In other words, we 
did not yet know what was distinctive 
about the IgG in IVIG that promoted 
this antiinfl  ammatory activity.
Why are high doses of IVIG 
results required?
If IVIG does not work by blocking 
FcγRs or FcRn, why are such high 
doses required? Recently, we explored 
the hypothesis that the antiinfl  ammatory 
activity of IVIG depends on a specialized 
subset of IgG that is present at limiting 
concentrations in the IVIG preparation. 
The glycosylation requirement for IVIG 
activity suggested that a specifi  c glyco-
form of the Asn297-linked glycan may 
be involved in the antiinfl  ammatory ac-
tivity. Because over 30 glycoforms are 
found at this position in human serum, 
the pooled serum used to prepare IVIG 
may contain limiting amounts of the 
antiinfl   ammatory IgG glycoform. We 
tested this hypothesis by fractionating 
IVIG and its Fc fragments by sialic 
acid–specifi  c lectin (SNA) affi   nity chro-
matography and found that 1–2% of 
unfractionated IVIG has sialic acid at 
the Asn297-linked glycan. Enrichment 
by SNA binding increased the sialic 
acid content to 20% with a concomi-
tant 10-fold increase in its antiinfl  am-
matory activity. In a mouse model of 
RA, 100 mg/kg of sialic acid–enriched 
IVIG protected as well as 1 g/kg of un-
fractionated IVIG. Further enrichment 
for the active glycoform of IgG should 
reduce this concentration requirement 
to 20 mg/kg or below. No diff  erence 
was observed in the serum half-life of 
the SNA-enriched IVIG compared 
with total IVIG, or in its requirement 
for FcγRIIB expression (31). These re-
sults are consistent with the model pro-
posed in Fig. 2, in which the sialylated 
IgG in normal serum engages a regula-
tory macrophage receptor with speci-
fi   city for the sialylated form of IgG, 
triggering an inhibitory pathway that 
ultimately results in the up-regulation 
of inhibitory FcγR expression on eff  ec-
tor macrophages. One candidate for the 
regulatory macrophage receptors are 
the siglec family of receptors (33), 
which bind sialic acid and have been 
suggested to mediate inhibitory signals 
via ITIM sequences found in their cy-
toplasmic domains.
Others have proposed that IVIG 
cross-linking of activating FcγRs on 
dendritic cells may contribute to the 
antiinfl  ammatory  eff  ects of IVIG in a 
model of ITP (24). These fi  ndings sug-
gest that under some experimental con-
ditions, ex vivo stimulation of dendritic 
cell populations through activating 
FcγRs may trigger antiinfl  ammatory 
responses, perhaps by promoting the 
diff  erentiation or survival of regulatory 
T cells. It is unlikely, however, that this 
mechanism is relevant to IVIG activity, 
as antibodies enriched in sialic acid show 
reduced binding to activating FcγRs 
yet display enhanced antiinfl  ammatory 
activity (27). The reduced binding of 
Figure 2.  Two-cell model for the mechanism of IVIG activity. Sialic acid–rich antibodies (red) 
in the IVIG preparation bind to an as yet unknown IVIG receptor on CSF-1–dependent regulatory 
macrophages. This induces the up-regulation of the inhibitory FcγRIIB on effector macrophages, 
thereby increasing the threshold for cell activation in response to the binding of immune complexes 
and inhibiting the release of destructive infl  ammatory and cytotoxic mediators.COMMENTARY
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the active glycoforms of IgG in IVIG 
to activating FcγRs bolsters the argu-
ment against the simple competition 
mechanism of IVIG action proposed in 
model 1.
Concluding remarks
The observation that IVIG activity is 
caused by a limiting concentration of a 
sialic acid–bearing IgG glycoform pro-
vides the rationale for the preparation 
of a sialic acid–enriched IVIG product 
that would confer greater antiinfl  am-
matory activity at doses 1/10 to 1/100 
currently required. It also suggests that a 
fully recombinant IVIG composed of 
hypersialylated IgG would be a potent 
antiinfl  ammatory agent for use in auto-
immune diseases. The identity of the 
macrophage receptor involved in the 
binding of sialylated IgG and the char-
acterization of the inhibitory pathways 
induced by sialylated IgG will provide 
insights into the normal biological func-
tions of sialylated IgG in vivo and the 
homeostatic pathways that regulate IgG 
eff  ector activity.
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